Sanofi India Ltd - 500674 - Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2023.
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended 30th June 2023. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Resignation of Director
We wish to inform you that Ms. Annapurna Das Non-Executive Director has resigned from the Board of Directors of the Company with effect from the close of business hours on 31 July 2023. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the company has approved issue of duplicate share certificates request in lieu of the original share certificate reported lost/misplaced. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, Company would like to inform the stock exchange that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate.
Sanofi India gets marketing nod for atopic dermatitis treatment medication
The company said Dupixent is the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies. Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the company has provided certificate for the quarter ended 30th June 2023 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations,2018. Corona Remedies acquires Myoril brand from Sanofi for 234 cr
The acquisition of Myoril gives Corona access to India's 1,626 crore muscle relaxant market Sanofi India Ltd - 500674 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons we would like to inform you that, inter-alia, for the purpose of declaration of financial results of the Company, for the quarter and half year ended 30th June 2023, the trading window of the Company shall remain closed from 1st July 2023 till 48 hours after the announcement of the results to the stock exchanges. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced